SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, as the company continues to expand the global footprint of its SSi Mantra surgical robotic system. The company's installations surged 30.4% to 30 during the quarter, reflecting accelerated adoption of its technology.
The financial results underscore a pivotal moment for the surgical robotics industry, where cost-effective solutions are becoming increasingly vital. SS Innovations' gross profit rose 20% to $7.1 million, with a gross margin of 50.9%, indicating strong operational efficiency even as the company invests heavily in regulatory approvals and market expansion. However, net loss widened to $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, as the company prioritizes long-term growth over short-term profitability.
For the first half of the fiscal year, revenue climbed 65.6% to $25 million, while installations of the SSi Mantra increased 47.4% to 56. As of June 30, SS Innovations had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. This financial stability positions the company to navigate the capital-intensive process of regulatory clearances and global commercialization.
The company also reported a cumulative 12,272 procedures performed using the SSi Mantra as of June 30, including 175 telesurgeries. Notably, SS Innovations recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's capability to deliver surgical expertise across vast distances. This achievement could have profound implications for healthcare access in underserved regions, where specialized surgical care is often scarce.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for the company to enter major markets, potentially reshaping the competitive landscape of robotic surgery.
The implications of this announcement extend beyond the company's financial performance. With the global surgical robotics market projected to grow significantly, the entry of a cost-effective player like SS Innovations could democratize access to robotic-assisted surgery, particularly in developing nations. The company's focus on affordability and user-friendliness aligns with the broader healthcare trend toward value-based care, where outcomes and cost-effectiveness are paramount.
For investors and industry observers, the robust revenue growth and expanding installed base signal strong market traction. However, the widening net loss highlights the substantial investment required to achieve regulatory approvals and scale operations. The company's cash position and lack of long-term debt provide a buffer, but sustained profitability will depend on successful regulatory outcomes and continued adoption of the SSi Mantra.
As SS Innovations progresses toward FDA and CE marking, its progress will be closely watched. The successful completion of long-distance telesurgeries already showcases the system's reliability and potential to bridge surgical gaps worldwide. With a growing installed base and a pipeline of regulatory milestones, the company is positioning itself as a key player in the evolution of surgical robotics.
